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ABSTRACT 
Aims: In recent years, stroke prevention in patients with atrial fibrillation (AF) has 
radically changed, with increasing use of non-vitamin K antagonist oral 
anticoagulants (NOACs). Contemporary European data on AF thromboprophylaxis 
are needed.  
Methods: We report 1-year follow-up data from the EURObservational Research 
Programme in Atrial Fibrillation (EORP-AF) General Long-Term Registry. Outcomes 
were assessed according to antithrombotic therapy.  
Results: At 1-year follow-up, 9663 (88.0%) patients had available data for analysis: 
586 (6.1%) were not treated with any antithrombotic; 681 (7.0%) with antiplatelets 
only; 4066 (42.1%) with vitamin K antagonist (VKA) only; 3167 (32.8%) with NOACs 
only; and 1163 (12.0%) with antiplatelet and oral anticoagulant (OAC). At 1-year 
follow-up, there was a low rate of stroke (0.7%) and any thromboembolic event [TE] 
(1.2%), while haemorrhagic events occurred in 222 patients (2.3%). Cardiovascular 
(CV) death and all-cause death occurred in 3.9% and 5.2% of patients respectively. 
Cumulative survival for all the three main outcomes considered was highest amongst 
patients treated only with NOACs (p<0.0001). Multivariable-adjusted Cox regression 
analysis found that VKA or NOACs use was independently associated with a lower 
risk for any TE/ACS/CV death, while all treatments were independently associated 
with a lower risk for CV death and all-cause death. 
Conclusions: The 1-year follow-up of EORP-AF General Long-Term Registry 
reported a low occurrence of thromboembolic and hemorrhagic events, although 
mortality was high. Both VKA and NOACs were associated with a lower risk of all 
main adverse outcomes. All treatments were associated with a lower risk for CV 
death and all-cause death. 
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CONDENSED ABSTRACT 
 
In a contemporary cohort of patients with atrial fibrillation, both VKA and NOACs 
were similarly associated with a lower risk of adverse outcomes as compared to no 
treatment. Furthermore, antiplatelet drugs are associated to a lower risk of death 
(despite with a lower magnitude) in patients with prominent cardiac disease.  
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INTRODUCTION 
Atrial fibrillation (AF) prevalence and incidence have been projected to substantially 
increase in the future, with more than 15 million Europeans to be affected by 2030 
and up to 215.000 new AF patients diagnosed each year1. Epidemiology of AF has 
changed in the last 15 years, with patients found to be older and more affected by 
cardiovascular (CV) and non-CV comorbidities2.  
 
AF is associated with an increased risk of stroke, with up to 30% of reported strokes 
being associated with AF; moreover, an increased risk of CV events, CV related 
death and all-cause death with AF has clearly been established3–6.  The introduction 
of the non-vitamin K antagonist oral anticoagulants (NOACs) as an effective and 
safer alternative to vitamin K antagonist (VKA)  has changed the landscape of 
clinical management for these patients7, although there are clear regional differences 
in prescription of these drugs8,9. 
 
In order to improve knowledge about AF natural history, association with risk factors 
and comorbidities and role of antithrombotic therapy in real-life, several 
observational registries have been conducted worldwide10–12. In 2012, the European 
Society of Cardiology (ESC) initiated the EURObservational Research Programme in 
AF (EORP-AF) General Pilot Registry, which was the first contemporary independent 
observational registry to provide a picture of the changing landscape of AF 
epidemiology and treatment in Europe, taking a snapshot of current practice 
amongst European cardiologists’ on the edge of the ‘NOAC era’3,13,14. In 2013, the 
EORP-AF General Long-Term Registry was launched with the aim to provide more 
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evidence about European AF patient characteristics, clinical practices and use of 
antithrombotic drugs after NOAC use was largely established in most of Europe8.  
In this paper we report the 1-year follow-up data of the EORP-AF General Long-
Term Registry, focusing on the relationship between baseline antithrombotic therapy 
use and the occurrence of major clinical adverse events. 
 
METHODS 
The EORP-AF General Long-Term Registry is a prospective, observational, 
multicenter registry established by ESC in 27 participating countries. The study 
enrolled consecutive AF patients presenting in 250 cardiology practices, both in- and 
outpatient settings. The detailed description of the design and baseline 
characteristics have been provided previously8. Briefly, all AF patients enrolled had 
AF documented within 12 months before enrollment on the basis of objective 
electrocardiographic evaluation. All patients were ≥18 years old and provided written 
informed consent form. Enrollment was undertaken from October 2013 to September 
2016, while 1-year follow-up was performed up until to September 2017. Institutional 
review board approved the study protocol for every institution, and the study was 
performed according to the EU Note for Guidance on Good Clinical Practice 
CPMP/ECH/135/95 and the Declaration of Helsinki8. 
 
Baseline information were collected according to study procedures previously 
described8. Thromboembolic risk was defined according to CHA2DS2-VASc score1. 
‘Low risk’ was defined as a CHA2DS2-VASc 0 in males and 1 in females; ‘moderate 
risk’ was defined for a CHA2DS2-VASc 1 in males; ‘high risk’ was defined as 
CHA2DS2-VASc ≥2. Bleeding risk was defined according to HAS-BLED score1. ‘Low 
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risk’ was defined as HAS-BLED 0-2, while ‘high risk’ was defined as HAS-BLED ≥3. 
Symptomatic status was defined according to EHRA (European Heart  Rhythm 
Association) score1. 
 
For the purpose of this analysis, patients were categorised according to 
antithrombotic therapy prescribed at discharge/after consultation, following 
enrolment in the study. Patients were then divided in five groups: 1) no 
antithrombotic therapy; 2) only antiplatelet drugs; 3) only VKA; 4) only NOACs; and 
5) antiplatelet drugs plus any oral anticoagulant (OAC). 
 
Follow-Up Procedures 
All follow-up was performed at 1-year after enrollment. During follow-up all incident 
major adverse clinical events were recorded, with the composite outcome of any 
thromboembolism (TE) (including stroke, transient ischemic attack and any 
peripheral embolism)/acute coronary syndrome (ACS)/CV death, CV death, all-
cause death as the main outcomes of interest.  
We also considered the individual outcomes of stroke, any TE, any hemorrhagic 
events and intracranial hemorrhage. Hemorrhagic events were not specifically 
defined, but all significant events which investigators became aware, were reported. 
All data about hospital admissions (any admission, AF-related and CV-related) were 
also recorded. Investigators reported all available details about incident major 
adverse clinical events on the centralized electronic case report form. Events are 
reported according to the five prespecified groups. 
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Statistical Analysis 
All continuous variables were reported as mean±SD or as median and interquartile 
range (IQR). Among-group comparisons were made using a non-parametric test 
(Kruskal-Wallis test. Categorical variables were reported as counts and percentages. 
Among-group comparisons were made using a chi-square test or Fisher’s exact test 
(if any expected cell count was less than five).  Plots of Kaplan-Meier curves for time 
to any TE/ACS/CV death, to cardiovascular deaths or to all-cause of death according 
to antithrombotic pattern were performed. Survival distributions were compared 
using the log-rank test. 
 
A univariate and stepwise multivariate Cox regression analysis, adjusted for all the 
main outcomes predictors in AF patients, was performed to establish the relationship 
between the various antithrombotic therapy patterns and the risk of the composite 
outcome of any TE/ACS/CV death, CV death or all-cause death. Into the model all 
the candidate variables (variables with p<0.10 in univariate) were included. A 
univariate significance level of 0.05 was required to allow a variable into the model 
(SLENTRY=0.05) and a multivariate significance level of 0.05 was required for a 
variable to stay in the model (SLSTAY=0.05). No interaction was tested. Hosmer and 
Lemeshow Goodness-of-Fit and Harrell’s C statistic tests were used to verify that the 
models were optimal. A two-sided p<0.05 was considered statistically significant. All 
analyses were performed using SAS statistical software version 9.4 (SAS Institute, 
Inc., Cary, NC, USA). 
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RESULTS 
Of the original 11096 patients enrolled in the EORP-AF General Long-Term Registry 
at baseline from October 2013 to November 2017, 121 (1.1%) withdrew their 
consent for the follow-up phase for their own personal choice, in accordance to good 
clinical practice. Of the remaining 10975 patients, 9663 (88.0%) had available data 
about follow-up status. The overall demographic and clinical characteristics of this 
cohort have been previously reported8. Baseline characteristics according to 
antithrombotic therapy prescribed at discharge are reported in Table 1.  
 
Patients prescribed with only antiplatelet drugs and antiplatelet drugs and OAC were 
older, with the latter ones were also less females (p<0.0001), while those not 
prescribed with any antithrombotic therapy were the youngest (p<0.0001) (Table 1). 
AF patients not prescribed with any antithrombotic therapy were generally less 
affected with concomitant cardiac diseases, CV risk factors and other comorbidities, 
while patients prescribed with both antiplatelet drugs and OAC were more likely 
diagnosed with most of those conditions. NOAC patients were more likely 
asymptomatic, compared to other groups (p<0.0001) (Table 1). In general, patients 
not prescribed with any antithrombotic therapy were less prescribed with other 
cardiovascular and non-cardiovascular drugs (Table S1).   
 
Baseline CHA2DS2-VASc score and proportion of patients with high thromboembolic 
risk (Table S2) were significantly lower in patients not prescribed with any 
antithrombotic, while it was progressively higher for patients prescribed only with 
NOACs, VKA, antiplatelet drugs, and with both antiplatelet drugs and OAC (all 
p<0.0001).  
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Similarly, HAS-BLED score (Table S2) and proportion of patients with high bleeding 
risk were lower in patients not prescribed with any antithrombotic therapy and 
progressively higher for patients prescribed only with NOACs, VKA, antiplatelet 
drugs and with both antiplatelet drugs and OAC (all p<0.0001). 
 
Use of Antithrombotic Therapy at 1-year Follow-up 
Antithrombotic therapy at follow-up visit discharge, according to baseline discharge 
antithrombotic therapy is shown in Figure 1. Almost half of the patients initially not 
prescribed with any antithrombotic were then prescribed with an antithrombotic drug, 
mostly NOACs (17.9%) [Figure 1, 1st column]; also, 33.3% of patients treated only 
with antiplatelet drugs at baseline were prescribed with an OAC, both alone and 
associated with antiplatelet drugs, at follow-up [Figure 1, 2nd column]. The large 
majority of patients originally prescribed with VKA or NOACs only remained on the 
same drugs, even though 4.5% and 7.9% respectively stopped taking their VKA and 
NOACs [Figure 1, 3rd and 4th columns]. Among patients treated with antiplatelet 
drugs and OAC, 41.7% were switched to a single OAC at follow-up [Figure 1, 5th 
column]. 
 
Follow-up Analysis 
After 1-year of follow-up observation, a total of 63 (0.7%) strokes, 116 (1.2%) any TE 
events and 148 (1.6%) ACS were recorded. A total of 222 (2.3%) hemorrhagic 
events, with 24 (0.3%) intracranial hemorrhages, as well as 380 (3.9%) CV death 
and 501 (5.2%) all-cause death events were also recorded. Overall, the composite 
outcome of any TE/ACS/CV death was recorded in 618 (6.5%). 
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Analyzing the occurrence of major adverse clinical events according to baseline 
antithrombotic therapy use at discharge (Table 2), a higher rate of stroke and any TE 
was recorded with antiplatelet drugs (1.7% [p=0.043] and 2.4% [p=0.053], 
respectively). No difference in rate of hemorrhagic events and intracranial 
hemorrhage was found. A higher rate of ACS, CV death and all-cause death was 
reported for both antiplatelet drugs and OAC, while the lowest rate was found in 
patients treated only with NOACs (all p<0.0001) (Table 2).  
 
The composite outcome of any TE/ACS/CV death was higher with antiplatelet drugs 
and those treated with both antiplatelet drugs and OAC (12.1% and 12.5% 
respectively) while patients treated only with NOACs reported the lowest rate (3.9%) 
(p<0.0001). Regarding hospital readmissions, patients treated both with antiplatelet 
drugs and OAC reported higher crude rates of any readmission and any CV 
readmission (Table 2). 
 
For the main outcomes of interest, overall incidence of any TE/ACS/CV death was 
6.6 per 100 patient-years, incidence of CV death was 3.9 per 100 patient-years and 
incidence of all-cause death was 5.2 per 100 patient-years. Patients treated only with 
antiplatelet drugs and those treated with both antiplatelet drugs and OAC reported 
the highest incidence rates (12.7 and 13.1 per 100 patient-years, respectively), while 
those not treated with any antithrombotic and those treated with VKA reported a 
similar incidence (5.5 and 6.1 per 100 patient-years, respectively); lastly those 
patients treated only with NOACs reported the lowest incidence (3.9 per 100 patient-
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years). Similar differences across the groups were found for CV death and all-cause 
death outcomes. 
 
Kaplan-Meier curves [Figure 2] show that the cumulative survival for any TE/ACS/CV 
death [Figure 2, Panel A] was highest for patients treated only with NOACs and 
progressively lower for patients treated only with VKA, patients not treated with any 
antithrombotic and those treated with antiplatelet drugs or antiplatelet drugs and 
OAC (p<0.0001). Similar evidence was reported for the CV death outcome [Figure 2, 
Panel B], while for all-cause death outcome, patients treated only with VKA or 
NOACs had similar cumulative survival, higher than those in other groups 
(p<0.0001) [Figure 2, Panel C]. 
 
Cox Regression Analysis 
After the univariate analysis (Table S3-S5), a Cox multivariate regression analysis 
(Table 3), adjusted for all the main known outcomes predictors in AF patients [Figure 
3, Panels A-C], showed an independent association with lower risk for any 
TE/ACS/CV death for patients treated only with VKA (hazard ratio [HR]: 0.44, 95% 
confidence interval [CI]: 0.31-0.63) and NOACs (HR: 0.37, 95% CI: 0.26-0.54), 
compared to those not treated with any antithrombotic therapy.  
 
For the CV death and all-cause death outcomes, all the antithrombotic therapies 
were associated to a lower risk of event occurrence, with treatment only with VKA or 
NOACs showing the lower risk (for CV death and all-cause death, only VKA, HR: 
0.38, 95% CI: 0.25-0.57 and HR: 0.34, 95% CI: 0.24-0.47, respectively; for only 
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NOACs, HR: 0.25, 95% CI: 0.16-0.40 and HR: 0.26, 95% CI: 0.18-0.38, 
respectively). 
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DISCUSSION 
In this 1-year follow-up report of the EORP-AF General Long-Term Registry, our 
principal findings are as follows: (i) we observed an overall low rate of 
thromboembolic, bleeding and CV events amongst a contemporary cohort of 
European AF patients, while conversely a higher rate of CV death and all-cause 
death was evident; (ii) after one year, the persistence of OAC treatments was high 
and most patients remained treated with at least one type of OAC; (iii) use of either 
VKA or NOACs was associated with a significant independent reduced risk for the 
composite of adverse clinical events. All the antithrombotic treatments (only 
antiplatelet drugs, only VKA, only NOACs and antiplatelet drugs and OAC) have 
been found to be associated with a lower risk of CV death and all-cause death, even 
though use of only VKA and only NOACs showed a stronger magnitude in risk 
reduction (Representative Figure). 
 
Results presented in this paper strengthen and reinforce the evidence, already 
provided in the baseline paper8, that the uptake of OAC (both VKA and NOACs) is 
very high and remains high persistently across 1-year of follow-up observation, also 
showing a significant reduction in use of aspirin. A recent study held in the UK, 
merging several different national databases further supported this observation in the 
context of a real-life scenario, reporting an increase in OAC uptake up to 78.6%, with 
a consensual decrease of antiplatelet drugs use up to 16.1%15. Notwithstanding, 
other nationwide real-life databases (based on general care and not on cardiology 
practices) even if confirmed an increase in OAC uptake (mostly based on the 
increased use of NOACs), reported an overall lower prescription rate compared to 
our data16,17. Further, the reduction in the use of aspirin was definitely more modest 
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than that described by our study16,17. These differences are likely to be attributed to 
the fact that our study is based on highly skilled and expert cardiology practices, also 
in the context of a specific study investigating cardiology practices in AF. 
 
Data from worldwide registries have established that oral anticoagulation is 
significantly associated with reduced rates of thromboembolic events10,11. Data from 
EORP-AF Pilot Registry reported a low rate of thromboembolic events, even though 
it was conducted when NOAC use was limited and also with a limited number of 
countries included3,14. Our data confirm and extend previous knowledge, 
demonstrating a high uptake of OAC treatment after NOACs fully entered current 
daily clinical practice in Europe, which are associated with a significantly reduced 
risk for thromboembolic complications, without an excess of bleeding complications. 
Even though the observational nature of the study does not allow to establish the 
causality link, the results presented seems to strengthen the concept that NOACs 
use is effective and safe in real-life AF population. Moreover, despite the observed 
differences in OAC prescription across European regions8, we found no impact of 
regions on outcomes, which did not emerge as significant independent predictors on 
multivariate analysis. 
 
Of note, the low rates of overall bleeding events possibly underlined how indications 
for appropriate management of modifiable bleeding risk score from international 
guidelines1 are implemented in cardiology clinical practice and effective in containing 
bleeding events. This appears to be particularly true regarding the intracranial 
hemorrhage events, which rates are extremely low (ranging from 0.2% to 0.3% in all 
the groups). Notwithstanding, this very low rate of events does not allow to draw 
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definitive conclusions regarding the difference in terms of intracranial bleeding 
between the various antithrombotic therapy approach. 
 
Despite the high use of OAC, the risk of CV death and all-cause death remained 
high in AF real-life patients. A post-hoc analysis derived from the ROCKET-AF trial 
also showed that the majority of deaths are related to cardiac causes associated with 
comorbidities5. In the Loire Valley Atrial Fibrillation project, after over a 2.5 years 
follow-up, 14% of patients died, with the majority of deaths  associated with pre-
existing cardiovascular comorbidities rather than stroke4. These data were also 
confirmed in the Phase III trials on NOACs18. Indeed, focus on the reduction of 
mortality is should be the next objective in improving outcomes for AF patients. This 
has led to the concept of ‘integrated care’ for improving management of AF patients, 
which has been shown to reduce mortality and hospitalizations19. Such ‘integrated 
care’ can be operationalized with the simple ABC pathway (‘A’ Avoid stroke with 
Anticoagulation; ‘B; Better symptom management with rate or rhythm control; ‘C’ 
Cardiovascular and comorbidity risk management, including lifestyle interventions)20.  
A more integrated, comprehensive evaluation of these patients would properly 
manage patients in a more holistic manner20,21. 
 
Follow-up data from large observational registries about AF patients have provided 
evidence about a sustained association of OAC and NOACs antithrombotic therapy 
with a reduced risk of thromboembolic events and death10,11. Our results supplement 
these industry-sponsored registries with an independent ESC-conducted European-
wide cohort of AF patients, where the use of VKA and NOACs was consistently 
associated with a reduced risk of main clinical adverse events, without an increase in 
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the risk of bleeding events. Our cohort included also AF patients not treated with 
VKA or NOACs (6% of the cohort) and this allows to make important considerations 
on this subgroup of “real-life” patients usually not object of analysis in other 
registries. Our data reinforce the concept that the use of any OAC is associated with 
a reduced risk of CV death and all-cause death, independently of known predictors 
of death in AF patients22.  
 
The association between use of antiplatelet drugs and reduced risk of CV death and 
all-cause death deserves some considerations. Current guidelines firmly 
contraindicate the use of antiplatelet drugs in patients with AF1, due to inefficacy to 
prevent stroke and the contemporary increased risk of major bleeding. Actually, both 
stroke and thromboembolic events are reported to be more than doubled in patients 
treated with antiplatelet drugs only. Conversely, no difference was found in the rate 
of hemorrhagic events, even though the overall low rate is likely due to the good 
implementation of current recommendations for minimizing bleeding risk as reported 
above.  
 
In the cohort of untreated patients more than 40% had a baseline high risk of stroke, 
which may have led to an overestimation of risk reduction in patients treated with 
antiplatelet drugs, even though still in this case the proportion of high risk is notable. 
Moreover, considering the high prevalence of cardiac disease associated to AF in 
these patients, that drive the prescription of antiplatelet drugs as described in other 
observational cohorts23, the inverse association with the risk of mortality can be due 
to an impact on the cardiac substrate, often due to relatively recent ACS8. 
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These considerations need to be extended also to those patients treated with both 
antiplatelet drugs and OAC. Indeed, these patients not only presented the highest 
baseline thromboembolic risk, but also reported the highest rate of events. 
Considering the baseline characteristics, we can see how these patients are the 
most burdened with coronary artery disease, previous myocardial infarction and 
peripheral artery disease. Our observations match with some recent papers 
specifically investigating this issue23,24. Even in these patients, very likely the 
combining action of OAC and antiplatelet drugs is able to modulate the 
cardiovascular risk associated with the vascular disease that goes beyond the AF-
related thromboembolic risk. 
 
Our observations surely do not allow to reconsider the role of antiplatelet drugs in 
thromboembolic risk management, but highlight the role of these drugs in the 
management of concomitant heart disease, that is often reported in AF patients, as 
underlined by clinical guidelines1. 
 
Limitations 
The main limitation of the study is related to the observational nature of the study. 
First, a significant number of patients were lost at follow-up, notwithstanding similar 
proportion of losses were reported by other registries11. Even though the events 
were not centrally adjudicated, this limitation is shared by almost all real-life 
observational registries. Moreover, if the low rate of thromboembolic events could be 
due to a relatively short follow-up, longer follow-up is planned to further substantiate 
our observations. Another limitation is related to the study setting, based exclusively 
on cardiology practices. Since AF patients are also commonly managed by different 
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health professionals (i.e. general practitioners, internal medicine specialists, 
geriatricians), our data need to be cautiously interpreted when extended to the entire 
AF population. 
 
CONCLUSIONS 
The one-year follow-up of EORP-AF General Long-Term Registry reported an 
overall low occurrence of thromboembolic and hemorrhagic events, although 
mortality was high. Both VKA and NOACs were similarly associated with a lower risk 
of the composite outcome of Any TE/ACS/CV death as compared to no treatment. 
All antithrombotic treatments are associated to a lower risk of CV death and all-
cause death, comprising antiplatelet drugs alone or in association with OAC (despite 
with a lower magnitude than only VKA and only NOACs) in patients with prominent 
cardiac disease.  
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Table 1: Demographic and Baseline Characteristics according to Antithrombotic Therapy at Baseline Discharge 
 No 
Antithrombotic 
Only Antiplatelet 
Drugs 
Only VKA Only NOACs Antiplatelet Drugs + 
OAC 
p 
 N= 586 N= 681 N= 4066 N= 3167 N= 1163  
Demographics       
Age, years Median [IQR] 61 [51-73] 72 [62-78] 71 [64-78] 70 [62-77] 72 [65-78] <0.0001 
Female, n (%) 223 (38.1) 289 (42.4) 1729 (42.5) 1272 (40.2) 374 (32.2) <0.0001 
Type of AF, n (%) 
First Diagnosed 
Paroxysmal 
Persistent 
LS Persistent 
Permanent 
 
136 (23.9) 
231 (40.7) 
78 (13.7) 
9 (1.6) 
114 (20.1) 
 
127 (19.2) 
285 (43.1) 
80 (12.1) 
18 (2.7) 
151 (22.8) 
 
386 (9.6) 
821 (20.5) 
711 (17.7) 
206 (5.1) 
1884 (47.0) 
 
626 (20.0) 
844 (27.0) 
814 (26.0) 
158 (5.1) 
683 (21.9) 
 
189 (16.7) 
288 (25.4) 
215 (19.0) 
35 (3.1) 
405 (35.8) 
<0.0001 
Concomitant Diseases 
Hypertension, n (%) 188 (32.5) 412 (61.1) 2631 (65.2) 1897 (60.4) 791 (68.5) <0.0001 
CAD, n (%) 91 (16.2) 334 (52.8) 850 (22.3) 498 (16.4) 834 (76.3) <0.0001 
Previous MI, n (%) 40 (44.0) 160 (47.9) 325 (38.2) 194 (39.0) 432 (51.8) <0.0001 
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Heart Failure, n (%) 135 (23.4) 323 (47.9) 1735 (42.9) 934 (29.8) 590 (51.1) <0.0001 
Valvular Disease, n (%) 157 (27.4) 305 (46.0) 2362 (59.1) 1316 (42.5) 625 (54.6) <0.0001 
Dilated Cardiomyopathy, n (%) 24 (4.2) 54 (8.0) 419 (10.4) 185 (5.9) 142 (12.4) <0.0001 
Hypertrophic Cardiomyopathy, n (%) 9 (1.6) 16 (2.4) 154 (3.8) 76 (2.4) 41 (3.6) 0.0007 
Restrictive Cardiomyopathy, n (%) 2 (0.3) 1 (0.1) 11 (0.3) 4 (0.1) 2 (0.2) 0.5788 
Other Cardiomyopathy, n (%) 12 (2.1) 24 (3.6) 161 (4.0) 97 (3.1) 56 (4.8) 0.0102 
Congenital Heart Disease, n (%) 6 (1.0) 9 (1.3) 50 (1.2) 25 (0.8) 12 (1.0) 0.3852 
PAH, n (%) 21 (3.7) 53 (8.0) 345 (8.6) 128 (4.1) 93 (8.1) <0.0001 
Cardiovascular Risk Factors 
Diabetes Mellitus, n (%) 86 (14.8) 161 (23.7) 943 (23.3) 595 (18.9) 409 (35.5) <0.0001 
Lipid Disorder, n (%) 148 (26.6) 295 (45.7) 1651 (42.5) 1138 (37.5) 617 (55.1) <0.0001 
Current Smoker, n (%) 85 (15.5) 71 (11.2) 305 (8.2) 244 (8.2) 124 (11.3) <0.0001 
No Regular Exercise, n (%) 170 (33.4) 290 (47.6) 1483 (42.5) 989 (37.0) 525 (50.9) <0.0001 
Other Comorbidities       
Previous Stroke, n (%) 14 (2.4) 40 (6.0) 262 (6.5) 189 (6.0) 83 (7.2) 0.0005 
Previous TIA, n (%) 6 (1.0) 18 (2.7) 126 (3.1) 119 (3.8) 41 (3.6) 0.0048 
Previous Bleedings, n (%) 39 (6.8) 59 (8.8) 166 (4.1) 163 (5.2) 68 (5.9) <0.0001 
PAD, n (%) 26 (4.5) 84 (12.8) 299 (7.5) 176 (5.7) 175 (15.5) <0.0001 
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Chronic Kidney Disease, n (%) 37 (6.3) 123 (18.2) 504 (12.5) 304 (9.6) 223 (19.3) <0.0001 
COPD, n (%) 34 (5.9) 60 (8.9) 388 (9.6) 226 (7.2) 147 (12.7) <0.0001 
Malignancy, n (%) 47 (8.0) 54 (8.0) 285 (7.0) 262 (8.3) 89 (7.7) 0.3309 
Thyroid Disease/Disorder, n (%) 57 (9.9) 75 (11.4) 615 (15.4) 452 (14.5) 166 (14.5) 0.0017 
Main Reason for 
Admission/Consultation, n (%) 
AF 
ACS 
Valvular Disease 
Hypertension 
Heart Failure 
Other CAD 
Other CV 
Other Non-CV 
 
 
447 (76.3) 
13 (2.2) 
9 (1.5) 
21 (3.6)  
22 (3.8) 
8 (1.4) 
28 (4.8) 
38 (6.5) 
 
 
368 (54.0) 
84 (12.3) 
19 (2.8) 
10 (1.5) 
 67 (9.8) 
41 (6.0) 
65 (9.5) 
27 (4.0) 
 
 
2565 (63.1) 
36 (0.9) 
177 (4.4) 
94 (2.3) 
502 (12.3) 
80 (2.0) 
363 (8.9) 
248 (6.1) 
 
 
2557 (80.7) 
19 (0.6) 
17 (0.5) 
51 (1.6) 
207 (6.5) 
36 (1.1) 
159 (5.0) 
121 (3.8) 
 
 
537 (46.2) 
161 (13.8) 
52 (4.5) 
19 (1.6) 
142 (12.2) 
96 (8.3) 
105 (9.0) 
51 (4.4) 
<0.0001 
Symptomatic Status, n (%) 
EHRA I 
EHRA II-III-IV 
 
261 (44.5) 
325 (55.5) 
 
337 (49.5) 
344 (50.5) 
 
1942 (47.8) 
2124 (52.2) 
 
1328 (41.9) 
1839 (58.1) 
 
519 (44.6) 
644 (55.4) 
<0.0001 
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Legend: ACS= Acute Coronary Syndrome; AF= Atrial Fibrillation; CAD= Coronary Artery Disease; COPD= Chronic Obstructive 
Pulmonary Disease; CV= Cardiovascular; EHRA= European Heart Rhythm Association; IQR= Interquartile Range; MI= Myocardial 
Infarction; NOACs= Non-vitamin K Antagonist Oral Anticoagulants; OAC= Oral Anticoagulants; PAD= Peripheral Artery Disease; 
PAH= Pulmonary Artery Hypertension; TIA= Transient Ischemic Attack; VKA= Vitamin K Antagonist.  
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Table 2: Major Adverse Clinical Events according to Antithrombotic Therapy at Baseline Discharge 
 No 
Antithrombotic 
Only Antiplatelet 
Drugs 
Only VKA Only NOACs Antiplatelet Drugs + 
OAC 
p 
 N= 586 N= 681 N= 4066 N= 3167 N= 1163  
Stroke, n (%) 2 (0.3) 11 (1.7) 22 (0.6) 20 (0.6) 8 (0.7) 0.0453 
Any TE, n (%) 9 (1.6) 16 (2.4) 40 (1.0) 37 (1.2) 14 (1.2) 0.0530 
Hemorrhagic Events, n (%) 8 (1.4) 15 (2.3) 95 (2.4) 74 (2.4) 30 (2.7) 0.5797 
Intracranial Hemorrhage, n (%) 1 (0.2) 2 (0.3) 12 (0.3) 6 (0.2) 3 (0.3) 0.8932 
Acute Coronary Syndrome, n (%) 6 (1.1) 27 (4.1) 49 (1.2) 24 (0.8) 42 (3.7) <0.0001 
CV Death, n (%) 17 (2.9) 47 (6.9) 157 (3.9) 64 (2.0) 95 (8.2) <0.0001 
All-Cause Death, n (%) 30 (5.1) 60 (8.8) 196 (4.8) 100 (3.2) 115 (9.9) <0.0001 
Any TE/ACS/CV Death, n (%) 31 (5.4) 81 (12.1) 240 (6.0) 122 (3.9) 144 (12.5) <0.0001 
Any Readmission, n (%) 120 (21.4) 176 (27.6) 912 (23.4) 723 (23.5) 326 (29.7) <0.0001 
Any AF Readmission, n (%) 48 (8.5) 67 (10.4) 405 (10.3) 354 (11.5) 135 (12.3) 0.0915 
Any CV Readmission, n (%) 85 (15.2) 151 (23.6) 745 (19.1) 561 (18.2) 278 (25.2) <0.0001 
Legend: ACS= Acute Coronary Syndrome; AF= Atrial Fibrillation; CV= Cardiovascular; NOACs= Non-vitamin K Antagonist Oral 
Anticoagulants; TE= Thromboembolism; OAC= Oral Anticoagulation; VKA= Vitamin K Antagonist. 
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Table 3: Cox Regression Analysis for Major Adverse Clinical Events according to Antithrombotic Therapy at Baseline Discharge 
 Any TE/ACS/CV Death* CV Death† All-Cause Death‡ 
 HR 95% CI p HR 95% CI p HR 95% CI p 
No Antithrombotic (ref.) - - - - - - - - - 
Only Antiplatelet Drugs 0.83 0.55-1.24 0.3619 0.56 0.34-0.91 0.0195 0.55 0.36-0.83 0.0041 
Only VKA 0.44 0.31-0.63 <0.0001 0.38 0.25-0.57 <0.0001 0.34 0.24-0.47 <0.0001 
Only NOACs 0.37 0.26-0.54 <0.0001 0.25 0.16-0.40 <0.0001 0.26 0.18-0.38 <0.0001 
Antiplatelet Drugs + OAC 0.71 0.48-1.04 0.0776 0.64 0.41-0.98 0.0402 0.57 0.40-0.83 0.0031 
Legend: *Hosmer and Lemeshow Goodness-of-Fit: 17.349, Harrell’s C statistic: 0.734; †Hosmer and Lemeshow Goodness-of-Fit: 
19.754, Harrell’s C statistic: 0.796; ‡Hosmer and Lemeshow Goodness-of-Fit: 19.152, Harrell’s C statistic: 0.780; ACS= Acute 
Coronary Syndrome; AF= Atrial Fibrillation; CV= Cardiovascular; NOACs= Non-vitamin K Antagonist Oral Anticoagulants; TE= 
Thromboembolism; OAC= Oral Anticoagulation; VKA= Vitamin K Antagonist.   
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FIGURE LEGENDS 
 
Figure 1: Antithrombotic Therapy at 1-year Follow-up Discharge according to 
Antithrombotic Therapy at Baseline Discharge 
Legend: NOACs= Non-vitamin K Antagonist Oral Anticoagulants; OAC= Oral 
Anticoagulation; VKA= Vitamin K Antagonist. 
 
Figure 2: Kaplan-Meier Curves for Major Adverse Clinical Events according to 
Antithrombotic Therapy at Baseline Discharge 
Legend: ACS= Acute Coronary Syndrome; AF= Atrial Fibrillation; CV= 
Cardiovascular; NOACs= Non-vitamin K Antagonist Oral Anticoagulants; TE= 
Thromboembolism; OAC= Oral Anticoagulation; VKA= Vitamin K Antagonist. 
 
Figure 3: Cox Multivariate Regression Analysis for Major Clinical Adverse 
Events according to Antithrombotic Therapy at Baseline Discharge 
Legend: Dashes stand for hazard ratio and 95% confidence interval. Reference for 
type of AF is first diagnosed, for enrollment year is 2013/2014 and for antithrombotic 
therapy is no antithrombotic; ACS= Acute Coronary Syndrome; AF= Atrial 
Fibrillation; CV= Cardiovascular; LS= Long-Standing; NOACs= Non-vitamin K 
Antagonist Oral Anticoagulants; TE= Thromboembolism; OAC= Oral Anticoagulation; 
TIA= Transient Ischemic Attack; VKA= Vitamin K Antagonist. 
 
Representative Figure: EORP-AF General Long-Term Follow-Up 
Legend: *the logical signs are intended as expressing the association between 
antithrombotic therapies and risk of outcomes occurrence and do not imply a 
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causative link; AP= Antiplatelet; CV= Cardiovascular; TE= Thromboembolism; 
NOACs= Non-vitamin K Antagonist Oral Anticoagulants; OAC= Oral Anticoagulation; 
VKA= Vitamin K Antagonist;  
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Table S1: Pharmacological Treatments at Discharge according to Antithrombotic Therapy at Discharge 
 No 
Antithrombotic 
Only Antiplatelet 
Drugs 
Only VKA Only NOACs Antiplatelet Drugs + 
OAC 
p 
 N= 586 N= 681 N= 4066 N= 3167 N= 1163  
Any Antiarrhythmic Drug, n (%) 144 (25.0) 175 (25.8) 1037 (25.6) 960 (30.3) 352 (30.4) <0.0001 
ACE Inhibitors, n (%) 119 (20.7) 331 (48.8) 1765 (43.6) 1174 (37.1) 645 (55.5) <0.0001 
ARBs, n (%) 43 (7.5) 94 (13.9) 793 (19.6) 704 (22.3) 220 (19.0) <0.0001 
DRI, n (%) 1 (0.2) 2 (0.3) 17 (0.4) 14 (0.4) 5 (0.4) 0.9605 
Beta Blockers, n (%) 257 (44.6) 497 (73.1) 2814 (69.4) 2184 (69.0) 911 (78.5) <0.0001 
Digoxin, n (%) 35 (6.1) 79 (11.7) 796 (19.6) 333 (10.5) 168 (14.5) <0.0001 
Diuretics, n (%) 107 (18.6) 309 (45.5) 2454 (60.6) 1312 (41.5) 742 (64.1) <0.0001 
Aldosterone Blockers, n (%) 32 (5.6) 112 (16.5) 903 (22.3) 338 (10.7) 324 (27.9) <0.0001 
DHP Calcium Channel Blockers, n (%) 50 (8.7) 125 (18.5) 668 (16.5) 568 (18.0) 222 (19.1) <0.0001 
Statins, n (%) 95 (16.5) 370 (54.7) 1632 (40.3) 1164 (36.8) 821 (70.8) <0.0001 
Oral Antidiabetics, n (%) 41 (7.1) 106 (15.6) 635 (15.7) 418 (13.2) 271 (23.4) <0.0001 
Insulin, n (%) 10 (1.7) 53 (7.8) 215 (5.3) 100 (3.2) 139 (12.0) <0.0001 
Thyroid Hormones, n (%) 28 (4.9) 47 (6.9) 388 (9.6) 266 (8.4) 109 (9.4) 0.0004 
Thyroid-Suppressing Drugs, n (%) 10 (1.7) 8 (1.2) 89 (2.2) 50 (1.6) 26 (2.2) 0.1777 
Legend: ACE= Angiotensin-Converting Enzyme; ARB= Angiotensin Receptor Blockers; DHP= Dihydropyridine; DRI= Direct Renin 
Inhibitor; NOACs= Non-vitamin K Antagonist Oral Anticoagulants; OAC= Oral Anticoagulation; VKA= Vitamin K Antagonist. 
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Table S2: Baseline Thromboembolic and Bleeding Risks according to Antithrombotic Therapy at Baseline Discharge 
 No 
Antithrombotic 
Only Antiplatelet 
Drugs 
Only VKA Only NOACs Antiplatelet Drugs + 
OAC 
p 
 N= 586 N= 681 N= 4066 N= 3167 N= 1163  
CHA2DS2-VASc 9659*       
Mean (SD) 1.94 (1.92) 3.38 (1.89) 3.26 (1.69) 2.89 (1.68) 3.75 (1.69) <0.0001 
Median [IQR] 1 [0-3] 3 [2-5] 3 [2-4] 3 [2-4] 4 [3-5] <0.0001 
TE Risk Classes, n (%) 
Low 
Moderate 
High 
 
238 (40.6) 
70 (11.9) 
278 (47.4) 
 
67 (9.8) 
56 (8.2) 
558 (81.9) 
 
244 (6.0) 
407 (10.0) 
3415 (84.0) 
 
311 (9.8) 
374 (11.8) 
2478 (78.3) 
 
28 (2.4) 
74 (6.4) 
1061 (91.2) 
<0.0001 
HAS-BLED       
Mean (SD) 0.95 (1.05) 2.08 (1.14) 1.60 (1.01) 1.26 (0.93) 2.28 (1.06) <0.0001 
Median [IQR] 1 [0-2] 2 [1-3] 2 [1-2] 1 [1-2] 2 [2-3] <0.0001 
Bleeding Risk Classes, n (%) 
Low 
High 
 
534 (91.1) 
52 (8.9) 
 
451 (66.2) 
230 (33.8) 
 
3381 (83.2) 
685 (16.8) 
 
2871 (90.7) 
296 (9.3) 
 
730 (62.8) 
433 (37.2) 
<0.0001 
Legend: *refers to patients with available data to calculate CHA2DS2-VASc score; IQR= Interquartile Range; NOACs= Non-vitamin 
K Antagonist Oral Anticoagulants; TE= Thromboembolic; OAC= Oral Anticoagulation; SD= Standard Deviation; VKA= Vitamin K 
Antagonist. 
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Table S3: Univariate Cox Regression Analysis for Any TE/ACS/CV Death 
 Univariate analysis 
 Effect* Hazard Ratio 95% CI p 
Antithrombotic pattern Antiplatelet + OAC 1.512 [1.094-2.091] <.0001 
 Only NOAC 0.459 [0.330-0.638] . 
 Only VKA 0.704 [0.518-0.956] . 
 Only antiplatelet 1.505 [1.058-2.141] . 
Entry Year 2015 0.660 [0.546-0.799] <.0001 
 2016 0.885 [0.731-1.071] . 
Region Northern Europe 0.640 [0.484-0.847] <.0001 
 Southern Europe 0.900 [0.736-1.101] . 
 Western Europe 0.533 [0.424-0.670] . 
Age (per ten years)  1.603 [1.478-1.739] <.0001 
Female gender Female 1.096 [0.937-1.281] 0.2503 
AF type LS persistent 0.691 [0.432-1.104] <.0001 
 Paroxysmal 0.725 [0.559-0.939] . 
 Permanent 1.312 [1.049-1.640] . 
 Persistent 0.586 [0.438-0.784] . 
Hypertension  1.075 [0.915-1.262] 0.3791 
Diabetes mellitus  1.600 [1.354-1.890] <.0001 
Coronary artery disease  2.494 [2.118-2.937] <.0001 
Previous Stroke/TIA  1.756 [1.406-2.193] <.0001 
Heart failure  2.809 [2.393-3.298] <.0001 
Any Cardiomyopathy  1.920 [1.595-2.312] <.0001 
Congenital Heart Disease  1.011 [0.480-2.130] 0.9768 
Peripheral vascular disease  2.094 [1.680-2.611] <.0001 
Chronic kidney disease  2.654 [2.227-3.162] <.0001 
Chronic obstructive pulmonary 
disease 
 1.701 [1.360-2.127] <.0001 
Lipid disorder  0.992 [0.845-1.165] 0.9210 
Malignancy  1.430 [1.109-1.845] 0.0059 
EHRA II-III-IV  1.003 [0.859-1.171] 0.9689 
Any Antiarrhythmic drug  0.667 [0.551-0.807] <.0001 
ACE-inhibitors  1.007 [0.861-1.177] 0.9342 
ARBs  0.914 [0.747-1.118] 0.3813 
DRI. Aliskiren  0.354 [0.050-2.516] 0.2995 
Beta Blockers  1.021 [0.863-1.208] 0.8084 
Digoxin  1.845 [1.536-2.216] <.0001 
Diuretics  2.120 [1.796-2.504] <.0001 
Aldosterone blockers  1.969 [1.661-2.333] <.0001 
DHP Calcium Channel Blockers  1.015 [0.827-1.247] 0.8842 
Statins  1.250 [1.071-1.459] 0.0046 
Oral antidiabetics  1.335 [1.097-1.625] 0.0040 
Insulin  2.115 [1.642-2.724] <.0001 
Thyroïd hormones  1.066 [0.816-1.394] 0.6376 
Thyroid-suppressing drugs  1.070 [0.618-1.853] 0.8097 
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Legend: Antithrombotic pattern: no Antithrombotic as reference; Type of AF: First 
diagnosed; Entry Year: 2013/2014; Region: Eastern Europe; Symptomatic status: 
EHRA I as Reference; CI= Confidence Interval. 
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Table S4: Univariate Cox Regression Analysis for CV Death 
 Univariate analysis 
 Effect* Hazard Ratio 95% CI p 
Antithrombotic pattern Antiplatelet + OAC 1.444 [0.977-2.136] <.0001 
 Only NOAC 0.363 [0.241-0.549] . 
 Only VKA 0.685 [0.473-0.991] . 
 Only antiplatelet 1.279 [0.828-1.978] . 
Entry Year 2015 0.584 [0.461-0.739] <.0001 
 2016 0.744 [0.586-0.944] . 
Region Northern Europe 0.468 [0.324-0.675] <.0001 
 Southern Europe 0.795 [0.624-1.013] . 
 Western Europe 0.458 [0.346-0.607] . 
Age (per ten years)  1.954 [1.752-2.179] <.0001 
Female gender Female 1.159 [0.953-1.410] 0.1401 
AF type LS persistent 0.796 [0.445-1.423] <.0001 
 Paroxysmal 0.657 [0.464-0.931] . 
 Permanent 1.628 [1.224-2.165] . 
 Persistent 0.543 [0.367-0.805] . 
Hypertension  1.080 [0.882-1.323] 0.4560 
Diabetes mellitus  1.543 [1.249-1.905] <.0001 
Coronary artery disease  2.355 [1.914-2.898] <.0001 
Previous Stroke/TIA  1.658 [1.244-2.208] 0.0006 
Heart failure  4.462 [3.580-5.561] <.0001 
Any Cardiomyopathy  2.591 [2.086-3.218] <.0001 
Congenital Heart Disease  1.166 [0.482-2.816] 0.7335 
Peripheral vascular disease  2.591 [2.000-3.357] <.0001 
Chronic kidney disease  3.468 [2.816-4.273] <.0001 
Chronic obstructive pulmonary 
disease 
 1.746 [1.322-2.305] <.0001 
Lipid disorder  0.830 [0.674-1.021] 0.0783 
Malignancy  1.628 [1.198-2.214] 0.0019 
EHRA II-III-IV  0.977 [0.804-1.188] 0.8177 
Any Antiarrhythmic drug  0.661 [0.519-0.843] 0.0008 
ACE-inhibitors  1.002 [0.823-1.221] 0.9831 
ARBs  0.768 [0.587-1.005] 0.0541 
DRI. Aliskiren  0.626 [0.088-4.434] 0.6389 
Beta Blockers  1.023 [0.828-1.264] 0.8349 
Digoxin  2.347 [1.890-2.915] <.0001 
Diuretics  3.532 [2.789-4.473] <.0001 
Aldosterone blockers  2.588 [2.111-3.174] <.0001 
DHP Calcium Channel Blockers  0.790 [0.596-1.048] 0.1017 
Statins  1.039 [0.854-1.265] 0.6999 
Oral antidiabetics  1.249 [0.971-1.607] 0.0834 
Insulin  2.309 [1.698-3.138] <.0001 
Thyroïd hormones  1.036 [0.736-1.459] 0.8381 
Thyroid-suppressing drugs  1.463 [0.803-2.663] 0.2136 
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Legend: Antithrombotic pattern: no Antithrombotic as reference; Type of AF: First 
diagnosed; Entry Year: 2013/2014; Region: Eastern Europe; Symptomatic status: 
EHRA I as Reference; CI= Confidence Interval. 
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Table S5: Univariate Cox Regression Analysis for All-Cause Death 
 Univariate analysis 
 Effect* Hazard Ratio 95% CI p 
Antithrombotic pattern Antiplatelet + OAC 1.118 [0.810-1.542] <.0001 
 Only NOAC 0.352 [0.253-0.489] . 
 Only VKA 0.539 [0.399-0.728] . 
 Only antiplatelet 1.029 [0.716-1.478] . 
Entry Year 2015 0.727 [0.590-0.896] 0.0073 
 2016 0.915 [0.740-1.130] . 
Region Northern Europe 0.678 [0.497-0.925] <.0001 
 Southern Europe 0.984 [0.786-1.231] . 
 Western Europe 0.627 [0.489-0.805] . 
Age (per ten years)  2.032 [1.846-2.236] <.0001 
Female gender Female 1.143 [0.964-1.356] 0.1232 
AF type LS persistent 0.656 [0.391-1.101] <.0001 
 Paroxysmal 0.626 [0.469-0.837] . 
 Permanent 1.383 [1.089-1.757] . 
 Persistent 0.490 [0.351-0.685] . 
Hypertension  1.106 [0.927-1.321] 0.2636 
Diabetes mellitus  1.557 [1.296-1.869] <.0001 
Coronary artery disease  2.084 [1.740-2.496] <.0001 
Previous Stroke/TIA  1.557 [1.207-2.008] 0.0007 
Heart failure  3.216 [2.687-3.850] <.0001 
Any Cardiomyopathy  2.290 [1.885-2.782] <.0001 
Congenital Heart Disease  1.059 [0.474-2.367] 0.8884 
Peripheral vascular disease  2.333 [1.849-2.944] <.0001 
Chronic kidney disease  3.268 [2.721-3.925] <.0001 
Chronic obstructive pulmonary 
disease 
 2.192 [1.753-2.741] <.0001 
Lipid disorder  0.811 [0.677-0.971] 0.0224 
Malignancy  2.240 [1.766-2.841] <.0001 
EHRA II-III-IV  0.908 [0.767-1.076] 0.2653 
Any Antiarrhythmic drug  0.637 [0.515-0.789] <.0001 
ACE-inhibitors  0.945 [0.795-1.123] 0.5232 
ARBs  0.755 [0.596-0.955] 0.0190 
DRI. Aliskiren  0.942 [0.235-3.770] 0.9323 
Beta Blockers  0.917 [0.765-1.098] 0.3464 
Digoxin  1.983 [1.630-2.413] <.0001 
Diuretics  2.824 [2.326-3.427] <.0001 
Aldosterone blockers  2.114 [1.759-2.540] <.0001 
DHP Calcium Channel Blockers  0.814 [0.639-1.038] 0.0967 
Statins  0.997 [0.840-1.183] 0.9693 
Oral antidiabetics  1.237 [0.993-1.541] 0.0579 
Insulin  2.320 [1.777-3.028] <.0001 
Thyroïd hormones  1.047 [0.778-1.408] 0.7615 
Thyroid-suppressing drugs  1.411 [0.830-2.399] 0.2029 
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Legend: Antithrombotic pattern: no Antithrombotic as reference; Type of AF: First 
diagnosed; Entry Year: 2013/2014; Region: Eastern Europe; Symptomatic status: 
EHRA I as Reference; CI= Confidence Interval. 
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